CRISPR AND CAS GENE MARKET ANALYSIS

Crispr and Cas Gene Market, By Product Type (Vector-based Cas, DNA-free Cas, and Others), By Application (Genome Engineering, Disease Models, Functional Genomics, Knockdown/Activation, and Others), By End User (Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Global Crispr and Cas Gene Market - Drivers

Increasing product launches by market players: Increasing product launches by the market players are expected to aid in the market growth over the forecast period. For instance, on June 21, 2021, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic, and pharmaceutical research, announced the launch of QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions that will help researchers to analyze edited gene material.
Increasing research and developmet activities by the Market Players: Increasing research and developmental activities by the market players is expected to propel the market growth over the forecast period. For instance, on April 27, 2023, a team of University of Florida researchers developed a promising new CRISPR-powered method for non-invasive blood tests that could help clinicians diagnose cancer at earlier stages. On December 2, 2019, Cyrus Biotechnology, Inc., a biotech company headquartered in Seattle, U.S. and the insititute of MIT and Harvard launched multi-target collaboration to develop optimized crispr gene editing technology.

Global Crispr and Cas Gene Market: Restraint

Limitations associated with crispr and cas gene: The relatively frequent off-target effects (OTEs), which have been found at a frequency of 50%, are a serious problem for using CRISPR/Cas9 for gene therapy. With increasing research and development gradually the limitation associated with crispr and Cas gene will get resolved.